A. Armstrong

发表

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

M. Augustin, C. Leonardi, K. Fahrbach, 2022, Dermatology and Therapy.

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey

R. Burge, E. Edson-Heredia, B. Zhu, 2022, Advances in Therapy.

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment

S. Ferrucci, E. Simpson, Zhen Chen, 2021, Dermatology and Therapy.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

A. Gottlieb, W. Campbell, L. Coates, 2016, Arthritis & rheumatology.

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17

M. Netea, B. Strober, M. Lebwohl, 2022, Dermatology and Therapy.

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders

B. Strober, J. Crowley, Tianshuang Wu, 2022, The Journal of dermatological treatment.

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3

J. Silverberg, M. Gooderham, A. Blauvelt, 2022, Dermatology and Therapy.

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

Vancomycin‐induced linear IgA disease manifesting as bullous erythema multiforme

Amin Fazeli, S. Yeh, B. Mackool, 2004, Journal of cutaneous pathology.

One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial.

B. Strober, M. Lebwohl, S. Piscitelli, 2022, Journal of the American Academy of Dermatology.

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

B. Strober, M. Lebwohl, S. Piscitelli, 2021, The New England journal of medicine.

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

M. Augustin, C. Leonardi, K. Fahrbach, 2022, Dermatology and Therapy.

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

B. Strober, M. Gooderham, K. Papp, 2022, Journal of the American Academy of Dermatology.

POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

B. Strober, M. Gooderham, K. Papp, 2021 .

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

B. Strober, M. Gooderham, A. Blauvelt, 2022, SKIN The Journal of Cutaneous Medicine.

Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis

Qian Xia, V. Patel, A. Armstrong, 2022, Dermatology and Therapy.

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

M. Witte, M. Gooderham, S. Ferrucci, 2023, JAMA dermatology.

Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes

P. A. Montgomery, B. Strober, Sepideh Parhami, 2022, SKIN The Journal of Cutaneous Medicine.

Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption

B. Keegan, G. Han, A. Armstrong, 2021, SKIN The Journal of Cutaneous Medicine.

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

K. Papp, K. Reich, A. Blauvelt, 2021 .

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey

M. Augustin, A. Armstrong, T. Kasparek, 2022, Dermatology and Therapy.

Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies

M. Praestegaard, P. Arenberger, L. Stein Gold, 2023, Dermatology and Therapy.

Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey

A. Armstrong, A. Bewley, R. Romiti, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

K. Reich, P. Foley, Chenglong Han, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

M. Lebwohl, A. Armstrong, A. Blauvelt, 2018, The British journal of dermatology.

The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel

D. Rigel, J. D. Del Rosso, B. Berman, 2023, SKIN The Journal of Cutaneous Medicine.

Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)

D. Rigel, L. Kircik, I. Kasujee, 2023, SKIN The Journal of Cutaneous Medicine.

Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)

D. Rigel, L. Kircik, I. Kasujee, 2023, SKIN The Journal of Cutaneous Medicine.

National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine

W. Liao, J. Koo, E. Siegel, 2023, JAAD international.